MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC) (MnSOD)
Chemotherapy (Paclitaxel and Carboplatin)and Thoracic Radiotherapy With Swallowed Manganese Superoxide Dismutase (MnSOD) Plasmid Liposome Protection in Patients With Locally Advanced Stage III Non-Small Cell Lung Cancer: A Phase I-II Study
Sponsor: Joel Greenberger
Terminated
MnSOD longer available during Phase II
Other Esophageal trials with similar outcome
Listed as NCT00618917, this PHASE1/PHASE2 trial focuses on Esophageal and Toxicity and remains terminated or withdrawn. Sponsored by Joel Greenberger, it has been updated 13 times since 2005, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE1_PHASE2
▶ Show 8 earlier versions
-
May 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Suspended → Terminated
-
Jan 2021 — May 2021 [monthly]
Suspended PHASE1_PHASE2
-
May 2020 — Jan 2021 [monthly]
Suspended PHASE1_PHASE2
-
Feb 2020 — May 2020 [monthly]
Suspended PHASE1_PHASE2
-
Feb 2019 — Feb 2020 [monthly]
Suspended PHASE1_PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Suspended PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Suspended PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE1_PHASE2
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Joel Greenberger
For direct contact, visit the study record on ClinicalTrials.gov .